Press release
Allergic Rhinitis Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trials, Companies and Market Insights
Curious about the latest updates in the Allergic Rhinitis Pipeline? Click here to explore the therapies and trials making headlines @ Allergic Rhinitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Allergic Rhinitis Pipeline Report
* On 16 September 2025, Advagene Biopharma Co. Ltd. announced a study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.
* DelveInsight's Allergic Rhinitis Pipeline report depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Allergic Rhinitis treatment.
* The leading Allergic Rhinitis Companies such as Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma and others.
* Promising Allergic Rhinitis Therapies such as GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10 and others.
Want to know which companies are leading innovation in Allergic Rhinitis? Dive into the full pipeline insights @ Allergic Rhinitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Allergic Rhinitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Allergic Rhinitis Pipeline Report also highlights the unmet needs with respect to the Allergic Rhinitis.
Allergic Rhinitis Overview
Allergic rhinitis (AR) is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. It affects one in six individuals and is associated with significant morbidity, loss of productivity, and healthcare costs. Historically, AR was thought to be a disease process of the nasal airway alone. Still, the development of the unified airway theory has classified AR as a component of systemic allergic response, with other associated conditions, such as asthma and atopic dermatitis, sharing an underlying systemic pathology.
Allergic Rhinitis Emerging Drugs
* REGN5713-5714-5715: Regeneron Pharmaceuticals
REGN5713-5714-5715 is a cocktail of three Bet v1 monoclonal antibodies. Regeneron Pharmaceuticals is investigating REGN5713-5714-5715 as intravenous injections in Phase III clinical studies for the treatment of allergic rhinitis and conjunctivitis.
* MM09-MG01: Immunotek
Inmunotek is developing a subcutaneously administered immunotherapy product MM 09, containing biological extracts of house dust mite, designated as M 601 (MM09-MG01). A Phase III Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen has been initiated.
If you're tracking ongoing Allergic Rhinitis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Allergic Rhinitis Treatment Drugs [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Allergic Rhinitis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Rhinitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Rhinitis Treatment.
* Allergic Rhinitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Allergic Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Rhinitis market.
Allergic Rhinitis Companies
Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma and others.
Allergic Rhinitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Allergic Rhinitis Products have been categorized under various Molecule types such as,
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
From emerging drug candidates to competitive intelligence, the Allergic Rhinitis Pipeline Report covers it all - check it out now @ Allergic Rhinitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Allergic Rhinitis Pipeline Report
* Coverage- Global
* Allergic Rhinitis Companies- Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma and others.
* Allergic Rhinitis Therapies- GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10 and others.
* Allergic Rhinitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Allergic Rhinitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Allergic Rhinitis Treatment landscape in this detailed analysis @ Allergic Rhinitis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Allergic Rhinitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* REGN5713-5714-5715: Regeneron Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IRL201104: Revolo Biotherapeutics
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* Allergic Rhinitis Key Companies
* Allergic Rhinitis Key Products
* Allergic Rhinitis- Unmet Needs
* Allergic Rhinitis- Market Drivers and Barriers
* Allergic Rhinitis- Future Perspectives and Conclusion
* Allergic Rhinitis Analyst Views
* Allergic Rhinitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=allergic-rhinitis-pipeline-drugs-report-2025-emerging-therapies-clinical-trials-companies-and-market-insights]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/allergic-rhinitis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Allergic Rhinitis Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trials, Companies and Market Insights here
News-ID: 4210457 • Views: …
More Releases from ABNewswire
Minimal Residual Disease Pipeline Outlook Report 2025: Drug Development, Clinica …
DelveInsight's "Minimal Residual Disease Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Minimal Residual Disease pipeline landscape. It covers the Minimal Residual Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Minimal Residual Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
NLRP3 Protein Inhibitors Pipeline Drug Report 2025 Insights: Advancing Therapies …
DelveInsight's "NLRP3 Protein Inhibitors Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the NLRP3 Protein Inhibitors pipeline landscape. It covers the NLRP3 Protein Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NLRP3 Protein Inhibitors Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Myasthenia Gravis Pipeline Outlook Report 2025: Novel Therapeutics, Clinical Adv …
DelveInsight's "Cushing Syndrome Pipeline Insight 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Autosomal Dominant Polycystic Kidney Disease Pipeline Drugs Report 2025: Innovat …
DelveInsight's "Autosomal Dominant Polycystic Kidney Disease Pipeline Insight 2025" report provides comprehensive insights about 13+ companies and 14+ pipeline drugs in the Autosomal Dominant Polycystic Kidney Disease pipeline landscape. It covers the Autosomal Dominant Polycystic Kidney Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
More Releases for Allergic
Prominent Allergic Rhinitis Market Trend for 2025: Advancements In Treating Nasa …
Which drivers are expected to have the greatest impact on the over the allergic rhinitis market's growth?
Anticipated growth in the allergic rhinitis market is predicted to be driven by increasing levels of air pollution and the impact of climate change. The term air pollution denotes the existence of harmful substances in our planet's atmosphere, which can negatively impact human health, damage the environment, and reduce the air's quality. Climate change…
Allergic Rhinitis: A Comprehensive Overview
Allergic rhinitis, commonly known as hay fever, is a condition where an individual's immune system overreacts to allergens in the air. These allergens, which may include pollen, dust, or pet dander, trigger inflammation inside the nose, leading to symptoms like sneezing, a runny nose, itchy eyes, and congestion. While often associated with the spring and fall seasons due to pollen levels, allergic rhinitis can affect individuals year-round, depending on the…
Allergic Conjunctivitis Market Statistics, Growth | Forecast
The new report published by The Business Research Company, titled ""Allergy Conjunctivitis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the allergy conjunctivitis market size has grown strongly in recent years. It will grow from $2.4 billion in 2023…
Anti-Allergic Drugs Market Overview 2030
Anti-allergic drugs represent a pivotal domain in healthcare, providing advanced solutions to alleviate symptoms triggered by allergens. With an ever-growing prevalence of allergies globally, the anti-allergic drugs market is witnessing a significant surge. Valued at USD 26,234 Million in 2021, the market is poised to skyrocket to USD 47,566 Million by 2030, showcasing a robust CAGR of 6.8%. In the United States alone, where allergies affect 40 to 50 million…
Allergic Conjunctivitis Market - Clear Eyes, Allergy-Free: Allergic Conjunctivit …
Newark, New Castle, USA: The "Allergic Conjunctivitis Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Allergic Conjunctivitis Market: https://www.growthplusreports.com/report/allergic-conjunctivitis-market/7892
This latest report researches the industry structure, sales, revenue,…
Allergic Conjunctivitis Market - Empowering Eyes, Enhancing Lives: Redefining Al …
Newark, New Castle, USA - new report, titled Allergic Conjunctivitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Allergic Conjunctivitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Allergic Conjunctivitis market. The report offers an overview of the market, which…
